Document:

EX-10.10

 Exhibit 10.10 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

THIRD AMENDMENT TO 

EXCLUSIVE DISTRIBUTION AGREEMENT 

This Third Amendment (this “Amendment”) to Exclusive Distribution Agreement is entered into as of December 31, 2013 (the
“Effective Date”), by and between Zimmer Dental Inc., a Delaware corporation (“Zimmer”), and RTI Biologics, Inc., a Delaware corporation (“RTI”). Unless otherwise defined herein, capitalized terms shall have the
meanings given to them in the Agreement (as defined below). 
 Recitals 

A.    Zimmer and RTI entered into an Exclusive Distribution Agreement on September 30, 2010, as amended on
September 27, 2011 (the “Agreement”). 
 B.    Zimmer and RTI desire to amend the Agreement and provide
for certain other matters as set forth in this Amendment. 
 Agreement 

For good and valuable consideration, the receipt and sufficiency of which are acknowledged by the execution and delivery of this Amendment,
Zimmer and RTI agree as follows: 
 1.    Marketing and Distribution Activities. The fifth
sentence of Section 2.3 of the Agreement is amended and replaced in its entirety with the following: [****] 

2.    Minimum Order Volume. The parties agree that the table in Section 3.9 of the Agreement that sets forth
the Minimum Requirements is deleted and replaced in its entirety with the following table: 
  

			
	 Calendar Year
	  	 Minimum Aggregate Fees

	2011	  	[****]
	2012	  	[****]
	2013	  	[****]
	2014	  	[****]
	2015	  	[****]
	2016	  	[****]
	2017	  	[****]
	2018	  	[****]
	2019	  	[****]
	2020	  	[****]

 3.    Representations and Warranties. Each Party hereby represents and warrants to
the other Party that the execution, delivery and performance by it of this Amendment and the consummation by it of the transactions contemplated hereby do not and will not violate, conflict with, result in the breach or termination of, or
constitute a default under (or event which, with notice, lapse of time or both, would constitute a default under), any contract or agreement to which it is a party or by which any of its properties or businesses are bound. 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 4.    Release and Waiver. [****]. 

5.    Effect on the Agreement. Except as specifically amended above, the Agreement shall remain in full force and
effect and is hereby ratified and confirmed. This Amendment is being effected in accordance with Section 13.4 of the Agreement. 

6.    Applicable Law. This Amendment shall be governed by and construed in accordance with the laws of the State of
Illinois, without regard to its choice of law rules. 
 [SIGNATURES ON FOLLOWING PAGE; 

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 IN WITNESS WHEREOF, each party has caused this Third Amendment to be executed by its
respective duly authorized representative as of the Effective Date. 
  

			
	RTI BIOLOGICS, INC.
		
	By:	 	/s/ Robert Lane
		
	Name:	 	Robert Lane
		
	Title:	 	Executive Vice President, Commercial
	
	ZIMMER DENTAL INC.
		
	By:	 	/s/ Harold C. Flynn, Jr.
		
	Name:	 	Harold C. Flynn, Jr.
		
	Title:	 	President, Zimmer DentalEX-10.11

 Exhibit 10.11 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

FIFTH AMENDMENT TO 

EXCLUSIVE DISTRIBUTION AGREEMENT 

This Fifth Amendment (this “Amendment”) to the Exclusive Distribution Agreement is entered into as the date of the
last signature below (the “Fifth Amendment Effective Date”) by and between RTI Surgical, Inc. (f/k/a RTI Biologics, Inc.), a Delaware corporation (“RTI”) and Biomet 3i, LLC, a Florida limited
liability company (“Biomet 3i”). Unless otherwise defined herein, capitalized terms shall have the meanings ascribed to such terms in the Agreement (as defined below). 

Recitals 

A.    Zimmer Dental, Inc. and RTI entered into an Exclusive Distribution Agreement on September 30, 2010, as
subsequently amended (the “Agreement”). 
 B.    Effective January 1, 2016, Zimmer Dental,
Inc. assigned the Agreement to its Affiliate, Biomet 3i. 
 C.    The Parties wish to incorporate additional EMEA Part
Numbers and Products to Exhibit A of the Agreement. 
 Agreement 

For good and valuable consideration, the receipt and sufficiency of which are acknowledged by the execution and delivery of this Amendment,
Biomet 3i and RTI agree as follows: 
 1.    Exhibit A. Exhibit A to the Agreement is hereby amended to
add the following Part Numbers and Product Descriptions (hereinafter the “Puros Blend Implants”): 
  

											
	     Part
Numbers
	 	 Brand/Product Description
	  	 Transfer
Fee
EMEA
	  	 Lead Time
(Calendar
Days)
	  	 Label
Shelf
Life
	  	 Minimum
Shelf Life

	67800	 	 Puros Blend, 0.5cm3, 250-1000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67801	 	 Puros Blend, 1.0 cm3, 250-1000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67802	 	 Puros Blend, 2.0 cm3, 250-1000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67803	 	 Puros Blend, 0.5 cm3,
1000-2000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67804	 	 Puros Blend, 1.0 cm3,
1000-2000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67805	 	 Puros Blend, 2.0 cm3,
1000-2000μ
	  	[****]	  	[****]	  	[****]	  	[****]
	67217*	 	 Puros Allograft Customized Block, Standard
	  	[****]	  	[****]	  	[****]	  	[****]
	67218*	 	 Puros Allograft Customized Block, Large
	  	[****]	  	[****]	  	[****]	  	[****]

 * [****] 

  

					
	RTI-Zimmer Biomet Dental – 5th Amendment to Exclusive Distribution Agreement	  	 	Page 1 of 3	 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 2.    Marketing Approvals. Notwithstanding any provision in the
Agreement to the contrary (including Section 6.3 and Exhibits E-1 and E-2), (a) RTI will be responsible for obtaining and maintaining the Marketing
Approvals for Biomet 3i to Distribute the Puros Blend Implants in [****], and, to the extent the Parties mutually agree to distribute the Puros Blend Products in the [****]; (b) Biomet 3i will be responsible for obtaining and maintaining the
Marketing Approvals for Biomet 3i to Distribute the Puros Blend Implants in [****] (provided, however, that the terms of Section 6.4(b) shall apply), the [****]; (c) RTI agrees to cooperate with Biomet 3i and provide any necessary
regulatory assistance as reasonably required by Biomet 3i in connection with the obtaining and maintaining of Marketing Approvals in the countries referenced in subsection (b) of this Section 2, but provides no assurances that such
Marketing Approvals will be obtained; (d) RTI will have primary responsibility for all communications, submissions and interactions with the applicable Regulatory Authorities for the purpose of obtaining and maintaining Marketing Approvals in
the countries referenced in subsections (a) of this Section 2; and (e) Biomet 3i will have primary responsibility for all communications, submissions and interactions with the applicable Regulatory Authorities for the purpose of
obtaining and maintaining Marketing Approvals in the countries referenced in subsection (b) of this Section 2. 

3.    Supply and Distribution Conditions. RTI shall have no obligation to supply Puros Blend Implants under the
Agreement in any particular country or jurisdiction until (1) the Puros Blend Implants have received the Marketing Approvals required in such country or jurisdiction; and (2) the Puros Blend Implants can be legally distributed under
Applicable Laws in such country or jurisdiction. The Parties acknowledge that the Puros Blend Implants satisfy the above conditions in the [****] market as of the Fifth Amendment Effective Date. To the extent the Puros Blend Implants are processed
in the [****] under the Agreement, the Parties shall execute a separate instrument setting forth their mutually agreed-upon pricing in USD. To the extent the Puros Blend Implants are processed in [****] under the Agreement, RTI shall bill Biomet 3i
in EUR and RTI agrees that Biomet 3i may designate its Affiliates as purchasers hereunder for Puros Blend Implants consistent with Section 3.6 of the Agreement. Section 3.1 of the Agreement shall not apply with regard to the Puros
Allograft Customized Blocks. Notwithstanding any provision to the contrary in the Agreement or any other instrument, Section 2.4 of the Agreement shall not apply to the Puros Blend Implants distributed in the [****] unless RTI obtains Marketing
Approval in such respective country. 
 4.    Termination of Amendment. RTI may terminate this Amendment and its
obligations to supply the Puros Blend Implants by providing Biomet 3i with one hundred eighty (180) days’ advance written notice if: (a) despite applying diligent, commercially reasonable efforts RTI is unable to maintain the
necessary Marketing Approvals for the Puros Blend Implants; (b) RTI experiences material difficulties in obtaining sufficient amounts of the precursor materials needed to manufacture the Puros Blend Implants where such difficulties last for
longer than ninety (90) consecutive days; or (c) discharging its obligation to supply the Puros Blend Implants would require RTI to expend a commercially unreasonable amount of time, money or other resources. 

  

					
	RTI-Zimmer Biomet Dental – 5th Amendment to Exclusive Distribution Agreement	  	 	Page 2 of 3	 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 5.    Effect on the Agreement. Except as specifically amended
above, the Agreement shall remain in full force and effect. This Amendment is being effected in accordance with Section 13.4 of the Agreement. 

IN WITNESS WHEREOF, each Party has caused this Amendment to be executed by its respective duly authorized representative as of the date set
forth below. 
  

									
	RTI SURGICAL, INC.	 		 	BIOMET 3i, LLC
					
	By:	 	/s/ Olivier Visa	 		 	By:	 	/s/ Indraneel Kanaglekar
					
	Name:	 	Olivier Visa	 		 	Name:	 	Indraneel Kanaglekar
					
	Title:	 	Vice President, OEM & Sports	 		 	Title:	 	Vice President
					
	Date:	 	October 11, 2017	 		 	Date:	 	October 11, 2017

  

					
	RTI-Zimmer Biomet Dental – 5th Amendment to Exclusive Distribution Agreement	  	 	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]